cbdMD Delivers on Sequential Revenue Growth and Positive Net Income for Q3 2024

Rhea-AI Summary

cbdMD, Inc. (NYSE American: YCBD) reported financial results for Q3 2024 ending June 30, 2024. Key highlights include:

- Net sales of $5.1 million, down 15% YoY but up 18% sequentially
- Gross profit improved to 65% from 63% in Q3 2023
- Operating loss reduced to $0.38 million from $1.8 million in Q3 2023
- Net income of $0.46 million compared to a net loss of $1.7 million in Q3 2023
- Cash on hand increased to $2.3 million from $1.8 million at fiscal year-end 2023

The company achieved significant operational efficiencies, with SG&A expenses down and the best non-GAAP adjusted EBITDA result in its history. However, cbdMD received a non-compliance notice from NYSE American and must submit a plan to regain compliance by December 5, 2025.

Positive

• Net sales increased 18% sequentially to $5.1 million
• Gross profit margin improved to 65% from 63% in Q3 2023
• Operating loss reduced significantly from $1.8 million to $0.38 million YoY
• Achieved net income of $0.46 million compared to a net loss of $1.7 million in Q3 2023
• Cash on hand increased to $2.3 million from $1.8 million at fiscal year-end 2023
• Achieved over $200,000 in monthly operating cost savings as of August 2024

Negative

• Net sales decreased 15% year-over-year to $5.1 million
• Direct-to-consumer sales decreased 20% year-over-year to $3.9 million
• Negative working capital of approximately $567,000 as of June 30, 2024
• Received non-compliance notice from NYSE American regarding continued listing standards
• Approximately $1.075 million remains on the principal balance of convertible promissory notes
• Past due rent payable owed to former landlord

Insights

Financial Analyst

cbdMD's Q3 2024 results show a mixed picture. While revenue decreased 15% year-over-year to $5.1 million, it grew 18% sequentially. The company achieved positive net income of $0.46 million, a significant improvement from the $1.7 million loss in Q3 2023. This was partly due to a non-cash gain from reduced convertible note value.

Operational efficiency improved markedly, with operating loss shrinking from $1.8 million to $0.38 million year-over-year. Gross margin increased to 65%, up from 63% in Q2 2023. However, the negative working capital of $567,000 and NYSE American compliance issues raise concerns about the company's financial stability.

While cost-cutting measures are showing results, the challenge remains in stimulating revenue growth in a competitive CBD market. Investors should monitor the company's ability to maintain profitability while investing in marketing to drive sales.

Market Research Analyst

The CBD market continues to face challenges, as evidenced by cbdMD's 15% year-over-year revenue decline. However, the 18% sequential growth suggests potential market stabilization. The direct-to-consumer (DTC) channel, accounting for 76% of total sales, remains important but saw a 20% year-over-year decline.

Interestingly, wholesale sales increased by 10%, indicating potential opportunities in brick-and-mortar retail. The introduction of new product lines like ATRx Labs (functional mushrooms) demonstrates the company's efforts to diversify beyond CBD, which could be important in a saturated market.

The focus on profitability over growth reflects a broader industry trend as the initial CBD boom subsides. Companies are now prioritizing operational efficiency and sustainable business models. cbdMD's ability to navigate this transition while maintaining brand strength will be critical for its long-term success in the evolving cannabis-adjacent product market.

cbdMD Achieves Significant Reduction in Operating Loss as Operational Efficiencies Significantly Improve in Q3 2024

Charlotte, North Carolina--(Newsfile Corp. - August 14, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs today announced our financial results for our third quarter of fiscal 2024 ending June 30, 2024.

This quarter, cbdMD made significant strides in its strategic objectives. Year-over-year, operational losses improved markedly, shrinking from $1.8 million in the third quarter of fiscal 2023 to $0.38 million in the third quarter of fiscal 2024.

"I am incredibly proud of what our team has accomplished this quarter," said Ronan Kennedy, CEO & CFO of cbdMD. "Profitability has been our top priority, and we've made meaningful progress in the fiscal third quarter. We committed to optimizing our cost structure, and as of August, we've delivered on those promises. With gross margins up, SG&A expenses down, and the best non-GAAP adjusted EBITDA result in our Company's history, we are moving in the right direction. While revenue growth in our category remains challenging, our focus remains on driving profits and enhancing shareholder value."

Financial Highlights from our Third Quarter of Fiscal 2024:

• Net sales totaled $5.1 million for the June 30, 2024 quarter or a decrease of 15% compared to $6.1 million for the prior year comparative fiscal quarter, but up 18% sequentially. For the nine months ended June 2024, Net sales totaled $14.9 million as compared to $18.4 million for the prior year period.

• We reported direct to consumer (DTC) net sales of $3.9 million or 76% of total net sales in the third quarter of fiscal 2024, a decrease from $4.9 million, or 20% from the third quarter of fiscal 2023, but an increase of 9% sequentially.

• We reported wholesale net sales of $1.2 million in the third quarter of fiscal 2024, an increase from $1.1 million, or 10% from third quarter of fiscal 2023.

• Our gross profit for the third quarter of fiscal 2024 totaled 65% in compared to 63% in the second quarter of fiscal 2023.

• Our loss from operations was $0.38 million during the third quarter of fiscal 2024 as compared to a loss of $1.8 million in third quarter of fiscal 2023.

• Our non-GAAP adjusted loss from operations during the third quarter of fiscal 2024 was approximately $0.08 million as compared to our non-GAAP adjusted loss from operations during the third quarter of fiscal 2023 of approximately $0.60 million, despite the decrease in overall revenue. This is the lowest non-GAAP adjusted EBITDA loss since cbdMD went public at the end of calendar 2018. For the nine months ended June 30, 2023 we reported non-GAAP EBITDA loss of $1.3 million as compared to $4.0 million in the prior year comparative period.

• Net income for the third fiscal quarter of 2024 was approximately $0.46 million, as compared to a net loss for the third fiscal quarter of 2023 of approximately $1.7 million. The improvement in the third fiscal quarter of 2024 was principally attributable to a $0.85 million non cash gain as a result of a reduction in the fair value of our convertible notes as well as operating improvements.

• Net loss attributable to common shareholders for third fiscal quarter of 2024 was approximately $0.5 million, or $0.15 per share, as compared to a net loss for the third fiscal quarter of 2023 of approximately $2.8 million, or $1.16 per share. The decrease in net loss in the third fiscal quarter of 2024 was principally attributable to operating improvements.

• At June 30, 2024, we had negative working capital of approximately $567,000. Our working capital is reduced by approximately $3.7 million of accrued dividend payments. At September 30, 2023 we had working capital of approximately $3.4 million, which was reduced by approximately $0.7 million for accrued dividends payable. In addition, at June 30, 2024 we had cash on hand of approximately $2.3 million as compared to cash on hand of approximately $1.8 million at September 30, 2023.

Highlights for the Third Quarter of 2024 and Notable Business Updates

• On June 5, 2024, the Company received notification from the NYSE American that the Company is no longer in compliance with NYSE American's continued listing standards. The notice provided that the Company must submit a plan of compliance by July 5, 2024 addressing how it intends to regain compliance with the continued listing standards by December 5, 2025. The Company timely submitted the plan to the NYSE American on July 5, 2024, advising of actions the Company intends to take to regain compliance with the continued listing standards. The Company expects to receive a response from NYSE American in mid August 2024.

• During the quarter, several convertible promissory notes holders elected to convert some of their accrued interested and principal balance, resulting in 714,229 common shares being issued during the third fiscal quarter of 2024. Approximately $1.075 million remains on the principal balance of the promissory notes.

• The Company has satisfied the recent agreements with its former landlord on the Red Oak Lease and effective August 1, 2024 has terminated its former executive office lease, eliminating the right of use asset and future lease liability from its balance sheet. The Company continues to have past due rent payable owed the landlord and continues to attempt to negotiate an amicable settlement. The Company's current facilities are sufficient for its current and future operations.

• The Company believes it has achieved over $200,000 in monthly operating costs savings as of August 2024. While it anticipates lower operating costs, it plans on increasing marketing costs during the fiscal fourth quarter of fiscal 2024.

We will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, August 14, 2024, to discuss our June 30, 2024, third quarter of fiscal 2024 financial results and business progress.

CONFERENCE CALL DETAILS

Wednesday August 14, 2024, 4:20 p.m. Eastern Time
USA/Canada:	844-763-8274
International:	647-484-8814
Teleconference Replay dial in:
USA/Canada:	877-344-7529
International:	412-317-0088
Replay Passcode:	5067217
Webcast/Webcast Replay link- available through August 14, 2025:	https://www.gowebcasting.com/13431

 

About cbdMD, Inc.

cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free¹ CBD products, including NSF Certified for Sport® products, as well as our new Full Spectrum products. Our cbdMD brand currently includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD sleep aids and CBD drink mixes and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and our ATRx brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free¹ CBD oil and Full Spectrum products as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, or ATRxlabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues, continued cost reductions, potential need for additional working capital, continued listing on the NYSE American, settlement of past due lease obligations, future profitability, development and sales of new products, and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 as filed with the Securities and Exchange Commission (the "SEC") on December 22, 2023, as amended on January 29, 2024, and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

¹ THC-free is defined as below the level of detection using validated scientific analytical methods.

Non-GAAP Financial Measures

This press release includes a financial measure that excludes the impact of certain items and therefore has not been calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). cbdMD, Inc. has included adjusted loss from operations because management uses this measure to assess operating performance in order to highlight trends in our business that may not otherwise be apparent when relying on financial measures calculated in accordance with GAAP. The adjusted operating loss has not been prepared in accordance with GAAP. This non-GAAP financial measure should not be considered as an alternative to, or more meaningful than, net loss from operations as an indicator of our operating performance. Further, this non-GAAP financial measure, as presented by cbdMD, Inc., may not be comparable to similarly titled measures reported by other companies. cbdMD, Inc. has attached to this press release a reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure.

cbdMD, INC.
CONSOLIDATED BALANCE SHEETS
June 30, 2024 AND SEPTEMBER 30, 2023
			(unaudited)
			June 30,			September 30,
			2024			2023
Assets
Cash and cash equivalents		$	2,395,175		$	1,797,860
Accounts receivable, net of allowance for credit losses of $268,948 and $42,180, respectively			915,988			1,216,090
Inventory			3,225,915			4,052,972
Inventory prepaid			79,866			182,675
Prepaid sponsorship			8,978			70,061
Prepaid expenses and other current assets			663,332			750,383
Total current assets			7,289,254			8,070,041
Other assets:
Property and equipment, net			553,067			716,579
Operating lease assets			2,468,466			3,350,865
Deposits for facilities			132,203			138,708
Intangible assets, net			2,700,564			3,219,090
Investment in other securities, noncurrent			700,000			700,000
Total other assets			6,554,300			8,125,242
Total assets		$	13,843,554		$	16,195,283
CONSOLIDATED BALANCE SHEETS
JUNE 30, 2024 AND SEPTEMBER 30, 2023
(continued)
			June 30,			September 30,
			2023			2023
Liabilities and shareholders' equity
Current liabilities:
Accounts payable		$	1,273,044		$	1,906,319
Accrued expenses			1,216,134			629,648
Accrued dividends			3,667,667			667,000
Deferred revenue			550,043			187,793
Operating leases - current portion			1,149,976			1,277,089
Note payable			-			2,492
Total current liabilities			7,856,864			4,670,341
Long term liabilities:
Convertible notes			1,378,000			-
Other long term liabilities			-			9
Operating leases - long term portion			1,580,569			2,403,286
Contingent liability			-			90,363
Total long term liabilities			2,958,569			2,493,658
Total liabilities			10,815,433			7,163,999
cbdMD, Inc. shareholders' equity:
Preferred stock, authorized 50,000,000 shares, $0.001
par value, 5,000,000 and 500,000 shares issued and outstanding, respectively			5,000			5,000
Common stock, authorized 150,000,000 shares, $0.001
par value, 3,759,433 and 2,960,573 shares issued and outstanding, respectively			3,759			2,961
Additional paid in capital			183,933,162			183,387,095
Comprehensive other expense			(1,200)			-
Accumulated deficit			(180,912,600)			(174,363,772)
Total cbdMD, Inc. shareholders' equity			3,028,121			9,031,284
Total liabilities and shareholders' equity		$	13,843,554		$	16,195,283

 

cbdMD, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2024 and 2023
(Unaudited)
			Three months			Three months			Nine Months			Nine Months
			Ended			Ended			Ended			Ended
			June 30			June 30			June 30			June 30
			2024			2023			2024			2023
Gross Sales		$	5,173,878		$	6,462,965		$	15,365,953		$	19,288,155
Allowances			-			(343,585)			(440,152)			(843,538)
Total Net Sales			5,173,878			6,119,380			14,925,801			18,444,617
Cost of sales			1,770,364			2,273,839			5,384,061			7,015,803
Gross Profit			3,403,514			3,845,541			9,541,740			11,428,814
Operating expenses			3,785,542			5,669,194			12,540,595			18,699,293
Loss from operations			(382,028)			(1,823,653)			(2,998,855)			(7,270,479)
(Increase) decrease of contingent liability			-			44,771			74,580			153,771
(increase) decrease in fair value of convertible debt			854,506			-			(591,494)			-
Other income			-			9,725			-			59,269
Interest expense			(12,741)			(1,246)			(31,558)			(5,831
Loss before provision for income taxes			459,737			(1,770,404)			(3,547,327)			(7,063,270)
Net Loss			459,737			(1,770,404)			(3,547,327)			(7,063,270)
Preferred dividends			1,000,500			1,000,501			3,001,501			3,001,503
Net Loss available to cbdMD, Inc. common shareholders		$	(540,763)		$	(2,770,904)		$	(6,548,828)		$	(10,064,773)
Net Loss per share:
Basic and diluted earnings per share		$	(0.15)		$	(1.16)		$	(1.84)		$	(4.26)
Weighted average number of shares Basic and Diluted:			3,592,969			2,379,633			3,561,884			2,360,908

 

cbdMD, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2024 and 2023
(Unaudited)
			Three months			Three months			Nine Months			Nine Months
			Ended			Ended			Ended			Ended
			June 30			June 30			June 30			June 30
			2024			2023			2024			2023
Net Income (loss)		$	459,737		$	(1,770,404)		$	(3,547,327)		$	(7,063,270)
Comprehensive Loss			459,737			(1,770,404)			(3,547,327)			(7,063,270)
Other Comprehensive Income (loss)			4,800			-			(1,200)			-
Preferred dividends			(1,000,500)			(1,000,501)			(3,001,501)			(3,001,503)
Comprehensive Loss attributable to cbdMD, inc. common shareholders		$	(535,963)		$	(2,770,904)		$	(6,550,028)		$	(10,064,773)

 

cbdMD, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE THREE AND NINE ENDED JUNE 30, 2024 AND 2023
(Unaudited)
				Nine Months			Nine Months
				June 30			June 30
				2024			2023
Cash flows from operating activities:
Net Loss			$	(3,547,327)		$	(7,063,270)
Adjustments to reconcile net loss to net
cash used by operating activities:
Stock based compensation				10,019			130,879
Restricted stock expense				2,073			105,101
Write off of prepaid assets due to termination of contractual obligation				-			884,892
Intangibles amortization				518,526			832,063
Depreciation				343,527			300,726
Increase (decrease) in contingent liability				(74,580)			(153,771)
Increase (decrease) in fair value of convertible debt				591,494			-
Amortization of operating lease asset				882,399			840,079
Changes in operating assets and liabilities:
Accounts receivable				253,361			336,091
Deposits				6,505			105,898
Inventory				827,057			424,079
Prepaid inventory				102,810			66,337
Prepaid expenses and other current assets				152,429			996,462
Accounts payable and accrued expenses				449,686			(1,172,306)
Operating lease liability				(949,829)			(876,526)
Deferred revenue / customer deposits				(88,319)			203,341
Collection on discontinued operations accounts receivable				-			1,375
Cash used by operating activities				(520,169)			(4,038,550)
Cash flows from investing activities:
Proceeds from sale of other investment securities				-			-
Purchase of property and equipment				(180,015)			(177,369)
Other securities				-			1,000,000
Cash used by investing activities				(180,015)			822,631
Cash flows from financing activities:
Proceeds from issuance of common stock				50,000			2,474,072
Note payable				1,247,499			(130,145
Preferred dividend distribution				-			(3,001,503
Cash used by financing activities				1,297,499			(657,576
Net decrease in cash				597,315			(3,873,495
Cash and cash equivalents, beginning of period				1,797,860			6,720,234
Cash and cash equivalents, end of period			$	2,395,175		$	2,846,739
Supplemental Disclosures of Cash Flow Information:
				2023			2022
Cash Payments for:
Interest expense			$	88,961		$	2,638
Non-cash financial activities:
Issuance of shares in exchange for a360 credit			$	-		$	1,531,999
Issuance of shares for conversion of debt and accrued interest			$	464,625		$	-
Preferred dividends accrued but not paid			$	3,001,501		$	-

 

cbdMD, Inc.
SUPPLEMENTAL FINANCIAL INFORMATION
RECONCILIATION OF NON-GAAP ADJUSTED LOSS FROM OPERATIONS
(unaudited)
			Three months			Three months			Nine Months			Nine Months
			Ended			Ended			Ended			Ended
			June 30			June 30			June 30			June 30
			2024			2023			2024			2023
GAAP loss from operations		$	(382,028)		$	(1,823,652)		$	(2,998,855)		$	(7,270,479)
Adjustments:
Depreciation & Amortization			287,754			375,579			862,053			1,132,789
Employee and director stock compensation (1)			9,321			61,016			16,835			315,982
Accrual for severence			-			-			-			129,761
Mergers and Acquistions and financing transaction expenses (2)			-			-			58,239			-
Non-cash expense incurred as a credit (3)			-			-			439,926			-
Non-cash accelerated amortization of expense related to terminated IT contracts			-			-			72,101			-
a-369 non-cash trade credit			-			778,703			-			887,039
Non-GAAP adjusted loss from operations		$	(84,953)		$	(608,354)		$	(1,549,701)		$	(4,804,908)

 

(1) Represents non-cash expense related to options, warrants, restricted stock expenses that have been amortized during the period.

(2) Represents expenses incurred in relation to M&A and financing activities during the nine months ended June 30, 2024.

(3) Represents non-cash expense incurred as a credit provided to GNC to replace expired product.

Contacts:

Investors:
cbdMD, Inc.
Ronan Kennedy
Chief Financial Officer
IR@cbdmd.com
(704) 445-3064

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219926

FAQ

What was cbdMD's (YCBD) revenue for Q3 2024?

cbdMD reported net sales of $5.1 million for Q3 2024, which ended on June 30, 2024. This represents a 15% decrease year-over-year but an 18% increase sequentially.

Did cbdMD (YCBD) achieve profitability in Q3 2024?

Yes, cbdMD reported a net income of $0.46 million for Q3 2024, compared to a net loss of $1.7 million in the same quarter of the previous year.

What is the status of cbdMD's (YCBD) NYSE American listing?

On June 5, 2024, cbdMD received a non-compliance notice from NYSE American regarding continued listing standards. The company must submit a plan by July 5, 2024, to regain compliance by December 5, 2025.

How much cash does cbdMD (YCBD) have on hand as of June 30, 2024?

As of June 30, 2024, cbdMD reported cash on hand of approximately $2.3 million, an increase from $1.8 million at the end of the previous fiscal year (September 30, 2023).